Item 2.02 Results of Operations and Financial Condition

On January 17, 2023, ADMA Biologics, Inc. (the "Company") issued a press release announcing its preliminary unaudited fourth quarter and full year 2022 revenues and providing 2023 financial guidance. A copy of the press release is furnished herewith as Exhibit 99.1.*



Item 9.01 Exhibits.



(d) Exhibits



Exhibit No. Description

  99.1      ADMA Biologics, Inc. Press Release, dated January 17, 2023
104         Cover Page Interactive Data File (embedded with the Inline XBRL document)


* The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.



                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses